Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease: Comparison between Belgium and the United States of a projected risk model

Atherosclerosis

Volumn 137, Issue SUPPL., 1998, Pages

  Muls, Erik ^a   Van Ganse, Eric ^b   Closon, Marie Christine ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Coronary heart disease; Cost effectiveness; Pharmacoeconomics; Pravastatin; Secondary prevention

Indexed keywords

PRAVASTATIN;

BELGIUM; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; HUMAN; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT OUTCOME; UNITED STATES;

ANTICHOLESTEREMIC AGENTS; BELGIUM; CORONARY DISEASE; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; FORECASTING; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, ECONOMIC; PRAVASTATIN; RISK FACTORS; SENSITIVITY AND SPECIFICITY; UNITED STATES;

EID: 0031749321     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00321-3     Document Type: Conference Paper

References (36)

1. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation 1994;89:1329.
2. Shepherd J, Cobbe S, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Engl J Med 1995;333:1301.
3. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383.
4. Superko HR, Krauss RM. Coronary artery disease regression. Convincing evidence for the benefit of aggressive lipoprotein management. Circulation 1994;90:1056.
5. Sarma S, Fifer SK. Gemfibrozil cost-benefit study. Targeting subgroups for effective hyperlipidaemia drug therapy. Drugs 1990;40(Suppl 1):42.
6. Assmann G, Schulte H. Primary prevention of coronary heart disease in the Federal Republic of Germany: a cost-effectiveness analysis. In: Lewis B, Assmann G, editors. The Social and Economic Contexts of Coronary Prevention. London: Current Medical Literature, 1990:37-56.
7. Glick H, Heyse JF, Thompson D, Epstein R, Smith ME, Oster G. A model for evaluating the cost-effectiveness of cholesterol-lowering treatment. Int J Technol Assess Health Care 1992;8:719.
8. Reckless J. Economic aspects of cardiovascular disease prevention. In: Woodford FP, Davignon J, Sniderman A, editors. Atherosclerosis X. Amsterdam: Elsevier, 1995:163-7.
9. Hamilton VH, Racicot F-E, Zowall H, Coupal L, Grover SA. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C. J Am Med Assoc 1995;273:1032.
10. Goldman L, Gordon D, Rifkind B, et al. Cost and health implications of cholesterol lowering. Circulation 1992;85:1960.
11. Pitt B, Mancini GBJ, Ellis SG, Rosman HS, Park J-S, Mc Govern M. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995;26:1133.
12. Crouse JR III, Byington RP, Bond MG, et al. Pravastatin, lipids and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995;75:455 Erratum, 75:862.
13. Ashraf T, Hay JR, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary heart disease. Am J Cardiol 1996;78:409.
14. Tsevat J, Duke D, Goldman L, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol 1995;26:914.
15. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Mak 1983;3:414.
16. Framingham Study, Section 35. Survival following initial cardiovascular events. US Department of Health and Human Services. NIH Pub No 88-2969. 1988;37-204.
17. Sigler LH. Long survival following myocardial infarction: report on 255 patients living 10 years or longer after the first attack. Am J Cardiol 1962;9:547.
18. Goldman L, Sia STB, Cook EF, Rutherford JD, Weinstein MC. Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. New Engl J Med 1988;319:152.
19. National Center for Health Statistics. Vital Statistics of the US, 1987, Mortality, Part A, Section 6:Life Tables. Government Printing Office, Washington, DC 1990;2:1-19.
20. Wittels E, Hay JW, Gotto A. Medical costs of coronary artery disease in the United States. Am J Cardiol 1990;65:432.
21. de Vreede JJ, Gorgels AP, Verstraaten GM, Vermeer F, Dassen WR, Wellens HJ. Did prognosis after myocardial infarction change during the past 30 years? A meta-analysis. J Am Coll Cardiol 1991;18:698.
22. Goldberg RJ, Gorak EJ, Yarzebski J, et al. A community wide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths caused by coronary heart disease. Circulation 1993;87:1947.
23. Gottlieb S, Moss AJ, Mc Dermott M, Eberly S. Comparison of post-hospital survival after acute myocardial infarction in women and men. Am J Cardiol 1994;74:727.
24. Merrilees MA, Scott PJ, Norris RM. Prognosis after myocardial infarction: results of 15 year follow-up. Br Med J 1984;288:356.
25. Launbjerg J, Fruergaard P, Madsen JK, Mortensen L, Hansen T. Ten-year mortality in patients with suspected myocardial infarction. Br Med J 1994;308:1196.
26. Herlitz J, Karlson BW, Hjalmarson A. Ten-year mortality among patients with suspected acute myocardial infarction in relation to early diagnosis. Cardiology 1994;84:114.
27. Closon MC. Etude des dépenses pharmaceutiques en fonction des pathologies des malades hospitalisés. Ministère de la Santé Publique: Administration des Etablissements de Soins, Brussels. 1992.
28. Closon MC. Le financement des hopitaux en fonction de la structure des pathologies. Thèse de doctorat. Ecole de Santé Publique, Faculté de Médecine, Université Catholique de Louvain. 1991.
29. Jönsson B, Johannesson M, Kjekshus J, Olsson AG, Pedersen T, Wedel H, for the Scandinavian Simvastatin Survival Study Group. Cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S). Eur Heart J 1996;17:1001.
30. Davie AP, Mc Murray JJV. Cost-benefit analysis of lipid lowering therapy. Eur Heart J 1996;17:974.
31. Tormans G, Van Damme P, Carrin G, Clara R, Eylenbosch W. Cost-effectiveness analysis of prenatal screening and vaccination against hepatitis B virus-the case of Belgium. Soc Sci Med 1993;37:173.
32. Arevalo JA, Washington AE. Cost-effectiveness of prenatal screening and immunization for hepatitis B virus. J Am Med Assoc 1988;259:365.
33. Laupacis A, Feeny D, Detsky A, Tugwell P. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J 1992;146:473.
34. Goldman L, Weinstein MC, Goldman PA, Williams LW. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart diseases. J Am Med Assoc 1991;265:1145.
35. Goldman L, Goldman PA, Williams LW, Weinstein MC. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993;72:75D.
36. Kupersmith J, Holmes-Rover M, Hogan A, Rovner D, Gardiner J. Cost-effectiveness analysis in heart disease, part II: preventive therapies. Prog Cardiovasc Dis 1995;37:243.